Intra-Cellular Therapies/ITCI

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX

About Intra-Cellular Therapies

Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

Ticker

ITCI

Sector

Healthcare

Trading on

NASDAQ

Industry

Pharmaceuticals

Headquarters

New York, United States

Employees

610

ITCI Metrics

BasicAdvanced
$7.2B
Market cap
-
P/E ratio
-$1.16
EPS
1.01
Beta
-
Dividend rate
$7.2B
1.01
5.123
4.501
2.125
2.732
-11.23%
-18.07%
12.85
11.1
11.1
-67.01
65.45%
-52.01%
139.08%
-28.21%

What the Analysts think about ITCI

Analyst Ratings

Majority rating from 17 analysts.
Buy

ITCI Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-10.49% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$145M
9.70%
Net income
-$15M
-46.67%
Profit margin
-10.49%
-51.41%

ITCI Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 49.61%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.45
-$0.25
-$0.30
-$0.16
-
Expected
-$0.59
-$0.57
-$0.44
-$0.32
-$0.18
Surprise
-23.75%
-55.83%
-32.23%
-49.61%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Intra-Cellular Therapies stock?

Intra-Cellular Therapies (ITCI) has a market cap of $7.2B as of July 04, 2024.

What is the P/E ratio for Intra-Cellular Therapies stock?

The price to earnings (P/E) ratio for Intra-Cellular Therapies (ITCI) stock is 0 as of July 04, 2024.

Does Intra-Cellular Therapies stock pay dividends?

No, Intra-Cellular Therapies (ITCI) stock does not pay dividends to its shareholders as of July 04, 2024.

When is the next Intra-Cellular Therapies dividend payment date?

Intra-Cellular Therapies (ITCI) stock does not pay dividends to its shareholders.

What is the beta indicator for Intra-Cellular Therapies?

Intra-Cellular Therapies (ITCI) has a beta rating of 1.01. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Intra-Cellular Therapies stock

Buy or sell Intra-Cellular Therapies stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing